Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concordance metrics (e.g., intraclass correlation) may not capture nuanced aspects of the association between clinician and patient-graded AEs, we aimed to characterize differences in AE grading thresholds between doctors (MDs), registered nurses (RNs), and patients using the Bayesian Graded Item Response Model (GRM)
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
We investigate the concordance, in terms of favoring the same treatment arm, between clinician-repor...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminolo...
Abstract Background Traditional concordance metrics have shortcoming...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Purpose Adverse symptom event reporting is vital as part of clinical trials and drug labeling to ens...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Many patients enter cancer clinical trials with baseline symptoms. Notably, the current clinician re...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
We investigate the concordance, in terms of favoring the same treatment arm, between clinician-repor...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminolo...
Abstract Background Traditional concordance metrics have shortcoming...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Purpose Adverse symptom event reporting is vital as part of clinical trials and drug labeling to ens...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Many patients enter cancer clinical trials with baseline symptoms. Notably, the current clinician re...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
We investigate the concordance, in terms of favoring the same treatment arm, between clinician-repor...